Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080222035
JPRN-jRCT2080222035UnknownPhase 3

An Open-label, Long-term Administration Study of S-8117 in Patients with Chronic Pain

SHIONOGI & CO., LTD.0 sitesStarted: March 7, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 79age old (—)
Sex
All

Inclusion Criteria

  • •Patients with pain for at least 12 weeks, and the pain is diagnosed as chronic pain such as osteoarthritis, diabetic neuropathy, or postherpetic neuralgia. And etc.

Exclusion Criteria

  • •Patients with previous or present allergy or hypersensitivity to opium alkaloids.
  • •Patients who participated in a clinical trial of S-8117 previously and received S-8117.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A 52-Week, Open-label, Multicenter Study of the Safety and Tolerabilityof Aripiprazole Flexibly Dosed in the Treatment of Children andAdolescents with Autistic DisorderAutistic disorder
EUCTR2017-000175-86-Outside-EU/EEAOtsuka Pharmaceutical Development & Commercialization,330
Active, not recruiting
Unknown
A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4)Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
KCT0008901ovo Nordisk29
Recruiting
Phase 3
A research study looking at long-term treatment withMim8 in people with haemophilia A
CTRI/2024/02/062683ovo Nordisk A/S
Recruiting
Phase 3
A research study looking at long-term treatment with Mim8 in people with haemophilia A(NN7769-4532)Participants with haemophilia A with or without FVIII inhibitors
JPRN-jRCT2041230047Esaki Risa425
Active, not recruiting
Not Applicable
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Ageno medical, conditionhealthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal strains A,C, W and Y.
EUCTR2007-001563-29-DEovartis Vaccines and Diagnostics S.r.l.250